174 related articles for article (PubMed ID: 37211857)
1. Evaluation of a photodynamic therapy agent using a canine prostate cancer model.
Luo D; Wang X; Ramamurthy G; Walker E; Zhang L; Shirke A; Naidu NG; Burda C; Shakya R; Hostnik ET; Joseph M; Ponsky L; Ponomarev V; Rosol TJ; Tweedle MF; Basilion JP
Prostate; 2023 Sep; 83(12):1176-1185. PubMed ID: 37211857
[TBL] [Abstract][Full Text] [Related]
2. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
3. A PSMA-targeted theranostic agent for photodynamic therapy.
Chen Y; Chatterjee S; Lisok A; Minn I; Pullambhatla M; Wharram B; Wang Y; Jin J; Bhujwalla ZM; Nimmagadda S; Mease RC; Pomper MG
J Photochem Photobiol B; 2017 Feb; 167():111-116. PubMed ID: 28063300
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
Wang Y; Abenojar EC; Wang J; de Leon AC; Tavri S; Wang X; Gopalakrishnan R; Walker E; MacLennan GT; Giles A; Czarnota GJ; Basilion JP; Exner AA
Prostate; 2022 May; 82(6):695-705. PubMed ID: 35167141
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.
Wang X; Ramamurthy G; Shirke AA; Walker E; Mangadlao J; Wang Z; Wang Y; Shan L; Schluchter MD; Dong Z; Brady-Kalnay SM; Walker NK; Gargesha M; MacLennan G; Luo D; Sun R; Scott B; Roy D; Li J; Basilion JP
Cancer Res; 2020 Jan; 80(2):156-162. PubMed ID: 31719100
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
[TBL] [Abstract][Full Text] [Related]
7. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.
Lütje S; Heskamp S; Franssen GM; Frielink C; Kip A; Hekman M; Fracasso G; Colombatti M; Herrmann K; Boerman OC; Gotthardt M; Rijpkema M
Theranostics; 2019; 9(10):2924-2938. PubMed ID: 31244933
[No Abstract] [Full Text] [Related]
9. Nanoparticles Yield Increased Drug Uptake and Therapeutic Efficacy upon Sequential Near-Infrared Irradiation.
Luo D; Wang X; Walker E; Wang J; Springer S; Lou J; Ramamurthy G; Burda C; Basilion JP
ACS Nano; 2020 Nov; 14(11):15193-15203. PubMed ID: 33090762
[TBL] [Abstract][Full Text] [Related]
10. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin.
Chang SC; Buonaccorsi G; MacRobert A; Bown SG
Int J Cancer; 1996 Aug; 67(4):555-62. PubMed ID: 8759616
[TBL] [Abstract][Full Text] [Related]
11. In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Choi JK; Berkman CE
Prostate; 2009 May; 69(6):585-94. PubMed ID: 19142895
[TBL] [Abstract][Full Text] [Related]
12. Development of an orthotopic canine prostate cancer model expressing human GRPr.
Tweedle MF; Ding H; Drost WT; Dowell J; Spain J; Joseph M; Elshafae SM; Menendez MI; Gong L; Kothandaraman S; Dirksen WP; Wright CL; Bahnson R; Knopp MV; Rosol TJ
Prostate; 2018 Jul; ():. PubMed ID: 29992622
[TBL] [Abstract][Full Text] [Related]
13. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.
Derks YHW; van Lith SAM; Amatdjais-Groenen HIV; Wouters LWM; Kip A; Franssen GM; Laverman P; Löwik DWPM; Heskamp S; Rijpkema M
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2425-2435. PubMed ID: 35029739
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
[TBL] [Abstract][Full Text] [Related]
15. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
Derks YHW; Schilham MGM; Rijpkema M; Smeets EMM; Amatdjais-Groenen HIV; Kip A; van Lith SAM; van de Kamp J; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Heskamp S; Lütje S
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2872-2884. PubMed ID: 37060367
[TBL] [Abstract][Full Text] [Related]
16. Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent.
Overchuk M; Damen MPF; Harmatys KM; Pomper MG; Chen J; Zheng G
Photochem Photobiol; 2020 May; 96(3):718-724. PubMed ID: 31742696
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.
Wang X; Sun R; Wang J; Li J; Walker E; Shirke A; Ramamurthy G; Shan L; Luo D; Carmon L; Basilion JP
Theranostics; 2022; 12(5):2335-2350. PubMed ID: 35265213
[No Abstract] [Full Text] [Related]
19. A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation.
Capozza M; Stefania R; Dinatale V; Bitonto V; Conti L; Grange C; Skovronova R; Terreno E
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361667
[TBL] [Abstract][Full Text] [Related]
20. Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model.
Schade GR; Keller J; Ives K; Cheng X; Rosol TJ; Keller E; Roberts WW
J Urol; 2012 Nov; 188(5):1957-64. PubMed ID: 22999534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
